---
schema_version: "secwatch.filing_event.v1"
accession: "0001663577-26-000046"
form_type: "8-K"
ticker: "BPTH"
cik: "0001133818"
company_name: "BIO-PATH HOLDINGS, INC."
filed_at: "2026-02-24T23:59:59+00:00"
generated_at: "2026-05-16T00:39:19.523747+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Bio-Path issues Series S preferred to CEO entity, giving 51% voting control; cancels reverse split, plans trial restarts

## Summary
- Issued 51 Series S preferred shares (1% vote each) and 2M warrants to CEO-controlled SGA, granting 51% voting control.
- $10K accrued payables used as consideration for the preferred and warrants; no new capital raised.
- Filing to domesticate to Wyoming from Delaware; expected approval March 2026.
- In talks with creditors to restructure; plans to restart Phase 1/2 trials for AML, solid tumors, and obesity.
- Canceled previously approved 1-30 reverse split; created Strategic Advisory Board and reserved 1.5M incentive stock options.

## SEC filing metadata
- accession: 0001663577-26-000046
- form_type: 8-K
- ticker: BPTH
- cik: 0001133818
- company_name: BIO-PATH HOLDINGS, INC.
- filed_at: 2026-02-24T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 5.01, 5.03, 7.1, 8.1
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1133818/000166357726000046/0001663577-26-000046-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1133818/000166357726000046/bpth_8k022426.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001663577-26-000046
- JSON: https://secwatch.observer/filing/0001663577-26-000046.json
- Plain text: https://secwatch.observer/filing/0001663577-26-000046.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.